Retevmo, an anticancer drug with mutations in RET, and Verquvo, a treatment for chronic heart failure, have entered into drug price negotiations with the NHIS. It is said that negotiations are still underway for Cibinqo, which started negotiations on drug prices in March, and Onureg, which started negotiations with the company last month. The NHIS recently updated its new drug price negotiation target through its website.

The newly updated information is that Verquvo 2.5, 5, and 10mg and Retevmo 40, 80mg were included in the drug price negotiations in June. The two drugs were recognized for their reimbursement adequacy at the 2023 5th Pharmaceutical Reimbursement Evaluation Committee held on the 4th of